Monthly Prescribing Reference

Pneumococcal 21-Valent Conjugate Vaccine Elicits Immune Response in Children at Increased Risk

Findings showed Capvaxive was noninferior to PPSV23 for each of the 12 serotypes present between the 2 vaccines. Topline data were announced from a phase 3 trial evaluating Merck’s 21-valent ...
Business Wire

CDC’S ACIP Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory ...
Benzinga.com

FDA Approves Merck's Pneumococcal Vaccine As First Shot Designed For Adults

Monday, the FDA approved Merck & Co Inc’s (NYSE: MRK) Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to protect against 21 strains of bacteria to prevent a severe form of pneumococcal disease.
Business Wire

Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from STRIDE-8, a Phase 3 trial evaluating CAPVAXIVE™ (Pneumococcal ...
Renal & Urology News

FDA Approves Capvaxive Pneumococcal 21-Valent Conjugate Vaccine

Company says vaccine covers serotypes responsible for approximately 84 percent of invasive pneumococcal disease in adults ages 50 years and older. (HealthDay News) — The US Food and Drug ...
Benzinga.com

Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data

Merck & Co. Inc. (NYSE:MRK) on Thursday released results from the Phase 3 STRIDE-13 trial evaluating Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) at the European Society of Clinical ...
Healio

Study provides more positive data on adult pneumococcal vaccine

Please provide your email address to receive an email when new articles are posted on . Researchers compared the 21-valent vaccine to a combination of a 15-valent and 23-valent vaccines. Fewer adverse ...
Yahoo

CDC: People over 50 should get pneumococcal vaccine

NEW YORK (AP) — A scientific panel on Wednesday recommended that people 50 and older get a shot against bacteria that can cause pneumonia and other dangerous illnesses. If the recommendation is ...
Healio

FDA approves Merck’s pneumococcal vaccine for adults

Please provide your email address to receive an email when new articles are posted on . Capvaxive is made to protect against strains of pneumococcus bacteria that cause disease in adults. A CDC ...
Monthly Prescribing Reference

FDA Approves 21-Valent Pneumococcal Conjugate Vaccine Capvaxive

Credit: Merck. Capvaxive consists of pneumococcal polysaccharides from 21 serotypes, including 8 unique serotypes: 15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B. Capvaxive consists of pneumococcal ...
Seeking Alpha

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck, known as MSD outside of the United States and Canada, today announced positive results from the Phase 3 STRIDE-13 trial evaluating CAPVAXIVE ® (Pneumococcal ...